Thank you for your interest in our Coronavirus analysis. As of Wednesday, June 30, 2021, our Coronavirus pipeline content is available through BCIQ and our Coronavirus analysis is included in our BioCentury subscription. If you are not a subscriber and would like to access our ongoing Coronavirus analysis, please sign up for a complimentary two-week subscription.
Already a subscriber? Simply log in and search for coronavirus to find the content.
License to Medicines Patent Pool will make the drug available in 105 low- and middle-income countries
FDA sees waning of protection against mild but not severe disease, hasn’t had time to do independent data analysis
BioCentury’s roundup of translational news
CDC panel recommendation would dial back FDA’s EUA, which itself was pared back from Pfizer’s request
Advisory committee meeting marked muddled messages from FDA, lack of coordination with Pfizer
FDA advisory committee will assess data on booster efficacy, risks of acting or waiting